BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"LC-MS" Keyword-tagged Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | International interlaboratory study to normalize liquid chromatography-based mycotoxin retention times through implementation of a retention index system | Kelman MJ; Renaud JB; McCarron P; Hoogstra S; Chow W; Wang J; Varga E; Patriarca A; Vaya AM; Visintin L; Nguyen T; De Boevre M; De Saeger S; Karanghat V; Vuckovic D; McMullin DR; Dall' Asta C; Ayeni K; Warth B; Huang M; Tittlemier S; Mats L; Cao R; Sulyok M; Xu K; Berthiller F; Kuhn M; Cramer B; Ciasca B; Lattanzio V; De Baere S; Croubels S; DesRochers N; Sura S; Bates J; Wright EJ; Thapa I; Blackwell BA; Zhang K; Wong J; Burns L; Borts DJ; Sumarah MW; | 39913989 CHEMBIOCHEM |
| 2 | Metabolomics 2023 workshop report: moving toward consensus on best QA/QC practices in LC-MS-based untargeted metabolomics | Mosley JD; Dunn WB; Kuligowski J; Lewis MR; Monge ME; Ulmer Holland C; Vuckovic D; Zanetti KA; Schock TB; | 38980450 CHEMBIOCHEM |
| 3 | Establishing a framework for best practices for quality assurance and quality control in untargeted metabolomics | Mosley JD; Schock TB; Beecher CW; Dunn WB; Kuligowski J; Lewis MR; Theodoridis G; Ulmer Holland CZ; Vuckovic D; Wilson ID; Zanetti KA; | 38345679 CHEMBIOCHEM |
| 4 | Metabolomics 2022 workshop report: state of QA/QC best practices in LC-MS-based untargeted metabolomics, informed through mQACC community engagement initiatives | Dunn WB; Kuligowski J; Lewis M; Mosley JD; Schock T; Ulmer Holland C; Zanetti KA; Vuckovic D; | 37940740 CHEMBIOCHEM |
| 5 | Comparative Analysis of Enzyme Production Patterns of Lignocellulose Degradation of Two White Rot Fungi: Obba rivulosa and Gelatoporia subvermispora | Marinovíc M; Di Falco M; Aguilar Pontes MV; Gorzsás A; Tsang A; de Vries RP; Mäkelä MR; Hildén K; | 35892327 CSFG |
| 6 | Dissemination and analysis of the quality assurance (QA) and quality control (QC) practices of LC-MS based untargeted metabolomics practitioners | Evans AM; O' Donovan C; Playdon M; Beecher C; Beger RD; Bowden JA; Broadhurst D; Clish CB; Dasari S; Dunn WB; Griffin JL; Hartung T; Hsu PC; Huan T; Jans J; Jones CM; Kachman M; Kleensang A; Lewis MR; Monge ME; Mosley JD; Taylor E; Tayyari F; Theodoridis G; Torta F; Ubhi BK; Vuckovic D; | 33044703 CONCORDIA |
| 7 | Proteomic Analysis of Morphologically Changed Tissues after Prolonged Dexamethasone Treatment | Malkawi AK; Masood A; Shinwari Z; Jacob M; Benabdelkamel H; Matic G; Almuhanna F; Dasouki M; Alaiya AA; Rahman AMA; | 31247941 CHEMBIOCHEM |
| 8 | Identification of novel enzymes to enhance the ruminal digestion of barley straw | Badhan A; Ribeiro GO; Jones DR; Wang Y; Abbott DW; Di Falco M; Tsang A; McAllister TA; | 29621684 CSFG |
| 9 | Mass Spectrometry-Based Proteomics | Marcos Rafael Di Falco | 29876812 CSFG |
| Title: | Proteomic Analysis of Morphologically Changed Tissues after Prolonged Dexamethasone Treatment | ||||
| Authors: | Malkawi AK, Masood A, Shinwari Z, Jacob M, Benabdelkamel H, Matic G, Almuhanna F, Dasouki M, Alaiya AA, Rahman AMA | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/31247941/ | ||||
| DOI: | 10.3390/ijms20133122 | ||||
| Publication: | International journal of molecular sciences | ||||
| Keywords: | LC-MS/M; dexamethasone; glucocorticoid side effects; label-free proteomics; network pathway; proteomic expression; rat tissues; | ||||
| PMID: | 31247941 | Category: | Int J Mol Sci | Date Added: | 2019-06-30 |
| Dept Affiliation: |
CHEMBIOCHEM
1 Department of Chemistry and Biochemistry, Concordia University, 7141 Sherbrook Street West, Montréal, QC H4B 1R6, Canada. 2 Department of Comparative Medicine, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh 11461, Saudi Arabia. 3 Proteomics Resource Unit, Obesity Research Center, College of Medicine, King Saud University, P.O. Box 2925 (98), Riyadh 11461, Saudi Arabia. 4 Stem Cell & Tissue Re-Engineering Program, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh 11461, Saudi Arabia. 5 Department of Genetics, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh 11461, Saudi Arabia. 6 College of Public Health, Medical, and Veterinary Sciences/Molecular & Cell Biology, James Cook University, Townsville, QLD 4811, Australia. 7 Department of Genetics, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh 11461, Saudi Arabia. aabdelrahman46@kfshrc.edu.sa. 8 College of Medicine, Al Faisal University, Riyadh 11533, Saudi Arabia. aabdelrahman46@kfshrc.edu.sa. 9 Department of Chemistry, Memorial University of Newfoundland, St. John's, NL A1B 3X7, Canada. aabdelrahman46@kfshrc.edu.sa. |
||||
Description: |
Prolonged dexamethasone (Dex) administration leads to serious adverse and decrease brain and heart size, muscular atrophy, hemorrhagic liver, and presence of kidney cysts. Herein, we used an untargeted proteomic approach using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for simultaneous identification of changes in proteomes of the major organs in Sprague-Dawley (SD rats post Dex treatment. The comparative and quantitative proteomic analysis of the brain, heart, muscle, liver, and kidney tissues revealed differential expression of proteins (n = 190, 193, 39, 230, and 53, respectively) between Dex-treated and control rats. Functional network analysis using ingenuity pathway analysis (IPA revealed significant differences in regulation of metabolic pathways within the morphologically changed organs that related to: (i) brain-cell morphology, nervous system development, and function and neurological disease; (ii) heart-cellular development, cellular function and maintenance, connective tissue development and function; (iii) skeletal muscle-nucleic acid metabolism, and small molecule biochemical pathways; (iv) liver-lipid metabolism, small molecular biochemistry, and nucleic acid metabolism; and (v) kidney-drug metabolism, organism injury and abnormalities, and renal damage. Our study provides a comprehensive description of the organ-specific proteomic profilesand differentially altered biochemical pathways, after prolonged Dex treatement to understand the molecular basis for development of side effects. |
